Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

639
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
Cancer Vaccines01:30

Cancer Vaccines

488
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
488
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

421
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
421

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moisturizing and repairing effects and mechanism of pullulans with different molecular weights on hair.

International journal of biological macromolecules·2026
Same author

High-dimensional immune profiling reveals NK cell dysregulation and neutrophil polarization after aneurysmal subarachnoid hemorrhage in delayed cerebral ischemia.

Scientific reports·2026
Same author

Hemocyanin modulates ferroptosis through a HSP90-dependent antioxidant function in shrimp.

Fish & shellfish immunology·2026
Same author

A method for constructing an installation accuracy control system for ultra-high-speed maglev supports considering known-point precision.

Scientific reports·2026
Same author

A dataset on morphology and composition of saltation-sandblasting dust particles from major Chinese source regions.

Scientific data·2026
Same author

Microbial enterotype is linked to episodic and working memories via brain function in the parietal and occipital cortices.

BMC biology·2026

Related Experiment Video

Updated: Aug 23, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

Clinical cancer immunotherapy: Current progress and prospects.

Chenglong Liu1, Mengxuan Yang1, Daizhou Zhang2

  • 1Minhang Hospital and Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.

Frontiers in Immunology
|October 28, 2022
PubMed
Summary

Immune checkpoint inhibitors, like PD-1 antibodies, offer significant survival benefits in cancer treatment. This review explores immunotherapy

Keywords:
CAR-Tcancer vaccinesimmune checkpoint inhibitorsimmunotherapytumor microenvironment

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

731
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

970

Related Experiment Videos

Last Updated: Aug 23, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

731
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

970

Area of Science:

  • Oncology and Immunology
  • Cancer Therapeutics
  • Immunotherapy Research

Background:

  • Cancer treatment has evolved, with immunotherapy, particularly immune checkpoint inhibitors targeting PD-1, emerging as a significant advancement.
  • PD-1 antibody therapy demonstrates notable clinical value, improving progression-free and overall survival rates in various cancers.
  • Despite its efficacy, cancer immunotherapy faces challenges including immune-related adverse events (irAEs), cytokine storms, and suboptimal response rates.

Purpose of the Study:

  • To review the classification, recent advancements, and inherent limitations of current cancer immunotherapy strategies.
  • To analyze mechanisms of immunotherapy resistance in cancer.
  • To provide insights into novel anticancer immunotherapy strategies by examining combination therapy approaches.

Main Methods:

  • Literature review of immune checkpoint therapy, focusing on PD-1 antibodies.
  • Analysis of cancer immunotherapy resistance mechanisms.
  • Evaluation of combination therapy approaches in the context of immunotherapy.

Main Results:

  • PD-1 antibody therapy shows significant clinical value and improves survival outcomes.
  • Cancer immunotherapy, while effective, is associated with limitations like irAEs and low response rates.
  • Understanding resistance mechanisms is crucial for developing improved combination therapies.

Conclusions:

  • Cancer immunotherapy represents a new era in oncology, offering substantial therapeutic potential.
  • Addressing limitations and resistance mechanisms through combination strategies is key to advancing immunotherapy.
  • Further research into novel immunotherapy strategies is essential for enhancing patient outcomes.